NASDAQ: LUMO - Lumos Pharma, Inc.

Yield per half year: +37.74%
Sector: Healthcare

Share chart Lumos Pharma, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its primary product candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 3 clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.

Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

Выручка 0.000936
EBITDA -0.0429
Число акций ао 0.00815 млрд
P/S 3.08
P/BV 0.0365
EV/EBITDA 2.01
Цена ао 2.88
ISIN US55028X1090
Сайт https://lumos-pharma.com
Валюта usd
IPO date 2011-11-11
Sector Health Care
Industry Biotechnology
Валюта отчета usd
Change price per day: -0.545% (3.67)
Change price per week: -4.95% (3.84)
Change price per month: -7.59% (3.95)
Change price per 3 month: +65.16% (2.21)
Change price per half year: +37.74% (2.65)
Change price per year: -10.76% (4.09)
Change price per 3 year: -65.89% (10.7)
Change price per 5 year: +128.13% (1.6)
Change price per year to date: +25.86% (2.9)
All parameters

Underestimation

Title Value Grade
P/S 12.07 1
P/BV 0.9068 9
P/E 0 0
EV/EBITDA 0.102 10
Total: 5

Efficiency

Title Value Grade
ROA, % -83.75 0
ROE, % -124.64 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0.0557

Debt

Title Value Grade
Debt/EBITDA -0.1801 10
Total: 9.8

Growth impulse

Title Value Grade
Yield Revenue, % 119.12 10
Yield Ebitda, % -14.76 0
Yield EPS, % -87.34 0
Total: 2.2
More

Institutions Volume Share, %
Wells Fargo & Company 417051 5.14
Goldman Sachs Group Inc 406611 5.02
Blackstone Inc 326552 4.03
Vanguard Group Inc 244082 3.01
Renaissance Technologies, LLC 221614 2.73
Acuitas Investments LLC 125282 1.55
Jefferies Financial Group Inc. 120651 1.49
Lion Point Capital, LP 90794 1.12
Greenwich Wealth Management LLC 76341 0.94
Bridgeway Capital Management, Inc. 47643 0.59

ETF Share, % Profitability for 1 year, % Dividends, %
Dimensional U.S. Equity ETF 0.00011 31.530984204131 1.3557



Head Job title Payment Year of birth
Mr. Richard J. Hawkins Founder, CEO & Chairman 854.35k 1949 (75 years)
Dr. John C. McKew Ph.D. Chief Scientific Officer & President 860.38k 1964 (60 years)
Ms. Lori D. Lawley CPA CFO & Principal Accounting Officer 538.23k 1984 (40 years)
Mr. Bradley J. Powers J.D. Chief Compliance Officer & General Counsel 677.08k 1979 (45 years)
Mr. Aaron Schuchart B.B.A., CPA, M.B.A. Chief Business Officer N/A 1966 (58 years)
Dr. Pisit Pitukcheewanont FAAP, M.D. Chief Medical Officer N/A
Mr. Eddie L. Varnado M.B.A. Corporate Controller N/A
Ms. Lisa Wells Miller Senior Director of Investor Relations N/A
Ms. Alpa Parikh Senior Vice President of CMC & Supply Management

Address: United States, Austin. TX, 4200 Marathon Boulevard - open in Google maps, open in Yandex maps
Website: https://lumos-pharma.com